Association between CCR5 genotype and the clinical course of HIV-1 infection

Ann Intern Med. 1997 Nov 15;127(10):882-90. doi: 10.7326/0003-4819-127-10-199711150-00004.

Abstract

Background: Heterozygosity for a 32-nucleotide deletion in the C-C chemokine receptor 5 gene (CCR5 delta 32) is associated with delayed disease progression in persons infected with HIV-1.

Objective: To compare the predictive value of CCR5 genotype with that of established markers in the clinical course of HIV-1 infection.

Design: Retrospective longitudinal study and nested case-control study. The latter included only long-term survivors, who were individually matched with progressors.

Setting: Amsterdam, the Netherlands.

Participants: 364 homosexual men with HIV-1 infection.

Measurements: Polymerase chain reaction was used for CCR5 genotyping. Univariate and multivariate Cox proportional hazard analyses were done for disease progression with CCR5 genotype, CD4+ T-lymphocyte counts, T-lymphocyte function, HIV-1 biological phenotype (syncytium-inducing or non-syncytium-inducing HIV-1), and viral RNA load in serum as covariates.

Results: In the case-control study, 48% of long-term survivors were heterozygous for CCR5 delta 32 compared with 9% of progressors (odds ratio, 6.9 [95% CI, 1.9 to 24.8]). In the total study sample, CCR5 delta 32 heterozygotes had significantly delayed disease progression (P < 0.001; relative hazard, 0.4 [CI, 0.3 to 0.6]), a 1.5-fold slower decrease in CD4+ T-lymphocyte count (P = 0.01), and a 2.6-fold lower viral RNA load (P = 0.01) at approximately 2.3 years after seroconversion compared with CCR5 wild-type homozygotes. At the end of the study, both groups showed the same prevalence of syncytium-inducing HIV-1, but CCR5 delta 32 heterozygotes had a delayed conversion rate. The protective effect of CCR5 delta 32 heterozygosity was stronger in the presence of only non-syncytium-inducing HIV-1. The CCR5 genotype predicted disease progression independent of viral RNA load, CD4+ T-lymphocyte counts, T-lymphocyte function, and HIV-1 biological phenotype.

Conclusions: The addition of CCR5 genotype to currently available laboratory markers may allow better estimation of the clinical course of HIV-1 infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / virology
  • Biomarkers / blood
  • CD4 Lymphocyte Count
  • Case-Control Studies
  • Disease Progression
  • Genotype
  • HIV Antibodies / blood
  • HIV Infections / blood
  • HIV Infections / virology*
  • HIV-1 / genetics*
  • Heterozygote
  • Humans
  • Life Tables
  • Longitudinal Studies
  • Male
  • Polymerase Chain Reaction
  • Proportional Hazards Models
  • Receptors, CCR5 / genetics*
  • Retrospective Studies
  • Viral Load

Substances

  • Biomarkers
  • HIV Antibodies
  • Receptors, CCR5